BoneFDA Approved

Calcitonin

Intranasal, Subcutaneous injection, Intramuscular injection

Overview

A 32-amino acid peptide hormone naturally produced by parafollicular C-cells of the thyroid gland. Calcitonin inhibits osteoclast-mediated bone resorption by binding to calcitonin receptors on osteoclasts, reducing their activity and number.

Mechanism of Action

Salmon calcitonin is approximately 40-50 times more potent than human calcitonin and has a longer half-life, making it the preferred therapeutic form..

Research Summary & Key Findings

FDA-approved for postmenopausal osteoporosis, Paget's disease, and hypercalcemia. PROOF trial demonstrated 33% reduction in vertebral fractures with nasal calcitonin 200 IU daily. Has analgesic properties for acute vertebral compression fractures independent of its anti-resorptive effects. Use has declined due to availability of more potent anti-resorptive agents and a small signal of increased malignancy risk with long-term use.

Clinical Status

FDA Approved

Calcitonin has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

IntranasalSubcutaneous injectionIntramuscular injection

Related Peptides in Bone

Find a Provider

Find a verified provider who offers Calcitonin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Calcitonin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.